Table1: Demographic and clinical characteristics of COVID-19 patients with diabetes.
|
Parameters |
Overall (N = 25) |
Survivors (13) |
Non-Survivors (12) |
P-value |
|
Age (Years) |
61 (41-85) |
60 (49-62) |
62 (56.5-66.5) |
0.181 |
|
Male |
17 (68%) |
7 (41%) |
10 (59%) |
0.202 |
|
Female |
8 (32%) |
6 (75%) |
2 (25%) |
|
|
Co-morbidity |
||||
|
HTN |
15 (60%) |
9 (60%) |
6 (40%) |
0.42 |
|
CLD |
1 (4%) |
0 |
1 (100%) |
0.12 |
|
CAD |
7 (28%) |
4 (57%) |
3 (43%) |
1.0 |
|
CKD |
9 (36%) |
1 (12%) |
8 (88%) |
0.004 |
|
TB |
2 (8%) |
2 (100%) |
0 |
0.48 |
|
CHF |
2 (8%) |
1 (50%) |
1 (50%) |
1.0 |
|
Malignancy |
2 (8%) |
0 |
2 (100%) |
0.22 |
|
Obesity |
2 (8%) |
0 |
2 (100%) |
0.22 |
|
ARDS |
14 (56%) |
6 (42.8%) |
8 (57.2%) |
0.43 |
|
SHOCK |
13 (52%) |
2 (15.4%) |
11 (84.6%) |
0.001 |
|
COVID Severity |
||||
|
Mild |
2 (8%) |
1 (50%) |
1 (50%) |
0.083 |
|
Moderate |
10 (40%) |
6 (60%) |
4 (40%) |
|
|
Severe |
13 (52%) |
6 (46%) |
7 (54%) |
|
|
Blood Sugar Level (First 3 consecutive days; gm/dl) |
||||
|
Day 1 |
278 (218-333) |
274 (97-327) |
282 (214-338) |
1.0 |
|
Day 2 |
296 (183-244) |
245 (183-298) |
330 (256-354) |
0.20 |
|
Day 3 |
229 (169-317) |
206 (169-285) |
270 (200-324) |
0.40 |
|
Management |
||||
|
OHA |
4 (16%) |
3 (75%) |
1 (25%) |
0.59 |
|
Insulin |
21 (84%) |
10 (47.6%) |
11 (53.4%) |
|
|
Steroids |
18 (72%) |
8 (44.4%) |
10 (55.5%) |
0.37 |
|
MV |
16 (64%) |
5 (31.3%) |
11 (68.7%) |
0.01 |
|
Outcome |
||||
|
ICU stay (days) |
8 (2-72) |
8 (6-14) |
9 (4.5-11.5) |
0.68 |
|
Hospital stays (days) |
13 (6-79) |
14 (10-19) |
12 (9.75-14.5) |
0.27 |
Data expressed as % and median as applicable
HTN: Hypertension; CLD: Chronic Liver Disease; CAD: Coronary Artery Disease; CKD: Chronic Kidney Disease; TB: Tuberculosis; CHF: Congestive Heart Failure; ARDS: Acute Respiratory Distress Syndrome; OHA: Oral Hyperglycemic Agent; MV: Mechanical Ventilation; ICU: Intensive Care Unit. p-value < 0.05 considered significant.